Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews the cutaneous side effects of immune checkpoint inhibitors and targeted therapies for skin cancers, noting that while generally mild, these effects can influence treatment decisions and quality of life, underscoring the need for physicians to be aware of these adverse reactions.

This report describes a case of polymyositis that was resistant to steroids and immunosuppressants but showed improvement with immunoadsorption therapy.

In this study, only a subset of proposed biomarkers universally responded to priming in mesenchymal stromal cells, suggesting limited utility for standardized potency assays across different MSC types and conditions.

This review highlights the potential of microneedles for immunotherapy, emphasizing their ability to enhance immune responses and reduce side effects through precise and stimuli-responsive delivery, especially in tumor treatment, while also noting the limitations and areas for improvement in current systems.

This study found that patients with alopecia areata receiving combined therapy showed a significant reduction in proinflammatory cytokines and circulating immune complexes, along with increased IL-10 levels and phagocytic activity, suggesting an immunomodulatory effect that reduces inflammation and restores immune balance.

Contact immunotherapy can change immune responses in alopecia areata, suggesting new treatment targets.

This review of sequential immunotherapy strategies for alopecia areata suggests that combining initial intensive immunosuppression with maintenance therapy may effectively manage disease progression by modulating inflammation and restoring immune tolerance.

This study reviews the mechanisms and recent findings of immunotherapies for NSCLC, highlighting their potential to improve treatment outcomes and reduce side effects compared to traditional therapies.

This review discusses the relationship between aging, chronic inflammation, and immunosuppression, suggesting that these interconnected processes may contribute to tumorigenesis and premature aging, but reports no new experimental results.

In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.

This study found that low-output laser irradiation demonstrates biostimulatory effects on several biological systems and processes, including hair growth, wound healing, and immune function, with effects influenced by dose and exhibiting both stimulatory and inhibitory potential.

This review examines various immunomodulatory therapies for cutaneous lymphoma and notes that they are most effective in the disease's early stages.

This study suggests that contact sensitizers may treat alopecia areata by expanding suppressor cells and interfering with antigen presentation to lymphocytes.

This review discusses the potential of combining low-dose IL-2 with islet antigens to enhance antigen-specific Treg function in type 1 diabetes, but reports no new clinical results.

This research developed new in vitro models for high-throughput screening of drugs that could protect or restore immune privilege in hair follicles, finding that Tofacitinib was effective in preventing inflammation-related marker upregulation, while Tacrolimus and αMSH worked specifically in outer root sheath keratinocytes.

This review highlights the possible role of T regulatory cells in the immune-related mechanisms of alopecia areata but reports no new clinical findings.

This study reported that using UVB preirradiation and anti-CD154 antibody treatment in a humanized mouse model prolonged hair follicle allograft survival and reduced immune cell infiltration without needing generalized immunosuppression.

This case study reports that immunotherapy with ipilimumab and nivolumab induced hypophysitis in a patient with renal cell carcinoma, emphasizing the need for careful monitoring of endocrine function in such treatments.

This study found that applying topical imiquimod during mid and late telogen in mice activates hair follicle stem cells and influences immune cell infiltration, promoting hair cycle entry independently of Wnt signaling.

This report describes a case of a patient with metastatic renal cell carcinoma who developed a psoriasiform skin lesion while undergoing immune checkpoint inhibitor therapy.

In this study, subcutaneous recombinant human IL-12 showed a 43% partial response rate in early-stage mycosis fungoides patients refractory to previous treatments, with generally mild to moderate adverse events reported.

Targeted immunological therapies offer safer and more effective treatments for skin conditions like eczema and psoriasis.

This study found that alopecia areata patients who responded poorly to topical immunotherapy had impaired peripheral blood mononuclear cell responses to T-cell stimulants.

This study found that coadministration of pimecrolimus may interfere with the therapeutic efficacy of mesenchymal stem cell therapy in atopic dermatitis.

This study found that the oral IRAK4-inhibitors BAY 1834845 and BAY 1830839 reduced skin inflammation and systemic inflammatory responses in healthy volunteers, showing similar pharmacodynamic effects to prednisolone when challenged with topical imiquimod and intravenous LPS.

This article provides a detailed analysis of immunosuppressive medications in transplant patients and discusses the increased risk of skin cancer, but it reports no new experimental results.

This review discusses the characteristics and treatment recommendations for skin-related adverse effects from immune checkpoint inhibitors in cancer treatment, and notes an observed association with favorable oncology outcomes that requires careful interpretation.

This study observed that expanding regulatory T cells in the skin of mice with alopecia areata did not reverse the condition, indicating that additional immunotherapy may be necessary.

This study found that imiquimod combined with fish oil in a bigel formulation enhanced antitumor effects and reduced inflammatory side effects in a skin cancer model.